- Home
- SEIC vs MDGL Comparison
SEIC vs MDGL Comparison
Compare SEIC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEIC
- MDGL
- Stock Information
- Founded
- SEIC 1968
- MDGL 2011
- Country
- SEIC United States
- MDGL United States
- Employees
- SEIC N/A
- MDGL N/A
- Industry
- SEIC Investment Bankers/Brokers/Service
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- SEIC Finance
- MDGL Health Care
- Exchange
- SEIC Nasdaq
- MDGL Nasdaq
- Market Cap
- SEIC 10.6B
- MDGL 9.6B
- IPO Year
- SEIC N/A
- MDGL N/A
- Fundamental
- Price
- SEIC $82.13
- MDGL $420.19
- Analyst Decision
- SEIC Buy
- MDGL Strong Buy
- Analyst Count
- SEIC 7
- MDGL 12
- Target Price
- SEIC $100.29
- MDGL $521.09
- AVG Volume (30 Days)
- SEIC 743.2K
- MDGL 270.6K
- Earning Date
- SEIC 10-22-2025
- MDGL 11-04-2025
- Dividend Yield
- SEIC 1.20%
- MDGL N/A
- EPS Growth
- SEIC 30.75
- MDGL N/A
- EPS
- SEIC 5.43
- MDGL N/A
- Revenue
- SEIC $2,246,646,000.00
- MDGL $515,547,000.00
- Revenue This Year
- SEIC $10.06
- MDGL $394.38
- Revenue Next Year
- SEIC $7.82
- MDGL $64.73
- P/E Ratio
- SEIC $15.10
- MDGL N/A
- Revenue Growth
- SEIC 9.44
- MDGL 3421.98
- 52 Week Low
- SEIC $64.66
- MDGL $201.22
- 52 Week High
- SEIC $93.96
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- SEIC 42.59
- MDGL 44.64
- Support Level
- SEIC $78.34
- MDGL $413.82
- Resistance Level
- SEIC $83.21
- MDGL $445.06
- Average True Range (ATR)
- SEIC 1.86
- MDGL 16.35
- MACD
- SEIC 0.00
- MDGL -3.80
- Stochastic Oscillator
- SEIC 48.53
- MDGL 17.11
About SEIC SEI Investments Company
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.